Article
Clinical Neurology
Ulla Knorr, Anja Hviid Simonsen, Camilla Steen Jensen, Henrik Zetterberg, Kaj Blennow, Morten Akhoj, Julie Forman, Steen Gregers Hasselbalch, Lars Vedel Kessing
Summary: This case-control study investigated the differences in biomarkers of amyloid and neurodegenerative diseases between patients with bipolar disorder (BD) and healthy control individuals. The results showed a decrease in CSF A beta 42 levels during BD episodes, but no significant differences were found in other markers between BD patients and healthy controls.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Article
Biochemistry & Molecular Biology
Ioanna Tsantzali, Fotini Boufidou, Eleni Sideri, Antonis Mavromatos, Myrto G. Papaioannou, Aikaterini Foska, Ioannis Tollos, Sotirios G. Paraskevas, Anastasios Bonakis, Konstantinos I. Voumvourakis, Georgios Tsivgoulis, Elisabeth Kapaki, George P. Paraskevas
Summary: Analysis of classical cerebrospinal fluid biomarkers, especially in the context of a diagnostic system like AT(N), can be a significant tool for diagnosing Alzheimer's disease accurately during a patient's lifetime. Despite atypical clinical presentations, the classical biomarker profile was consistent with Alzheimer's disease in four patients, demonstrating the potential usefulness of these biomarkers for identifying the biochemical fingerprints of the disease.
Article
Medical Laboratory Technology
Anders Abildgaard, Tina Parkner, Cindy Soendersoe Knudsen, Hanne Gottrup, Henriette Klit
Summary: This study found that tau/Aβ 42 ratios have the best diagnostic performance, but the estimated cut-off values for the ratios were slightly higher than previously reported. Therefore, adjustment of the cut-offs may be warranted when using CSF analysis to support a diagnosis of AD in a heterogeneous high-prevalence cohort.
CLINICA CHIMICA ACTA
(2023)
Article
Neurosciences
Soyeon Kim, Kiwon Kim, Kwangsik Nho, Woojae Myung, Hong-Hee Won
Summary: The study found a causal association between CSF biomarkers and the risk of LOAD, suggesting that the etiology of LOAD involves pathways of A beta and tau proteins. Further MR studies using large-scale data are needed to elucidate the pathophysiology of LOAD.
JOURNAL OF ALZHEIMERS DISEASE
(2021)
Review
Neurosciences
Donovan A. McGrowder, Fabian Miller, Kurt Vaz, Chukwuemeka Nwokocha, Cameil Wilson-Clarke, Melisa Anderson-Cross, Jabari Brown, Lennox Anderson-Jackson, Lowen Williams, Lyndon Latore, Rory Thompson, Ruby Alexander-Lindo
Summary: This review presents the current evidence on CSF biomarkers for Alzheimer's disease, emphasizing the efficacy of existing core biomarkers and the need for further development of biomarkers reflecting other aspects of the disease mechanism. It also introduces new biomarkers that track Alzheimer's disease pathology and their potential in diagnosis and predicting cognitive decline.
Article
Medical Laboratory Technology
Rosa Ferrer, Nuole Zhu, Javier Arranz, Inmaculada Porcel, Shaimaa El Bounasri, Oriol Sanchez, Soraya Torres, Josep Julve, Alberto Lleo, Francisco Blanco-Vaca, Daniel Alcolea, Mireia Tondo
Summary: This study aimed to investigate the potential influence of different storage conditions on the quantification of biomarkers related to Alzheimer's disease in cerebrospinal fluid. The results showed that temperature and storage days significantly impacted the concentrations of certain biomarkers. However, the use of a ratio between two biomarkers could partially compensate for this influence. Other biomarkers were not affected by the tested storage conditions. The findings suggest that specific correction factors can be applied for samples stored at 4 degrees C.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2022)
Review
Chemistry, Analytical
Arezoo Mirzaie, Hassan Nasrollahpour, Balal Khalilzadeh, Ali Akbar Jamali, Raymond J. Spiteri, Hadi Youse, Ibrahim Isildak, Reza Rahbarghazi
Summary: Alzheimer's disease is a prevalent neurodegenerative disorder characterized by progressive deterioration, loss of neurons, and cognitive decline. Amyloid beta and Tau proteins are key biomarkers of the disease, and their abnormal levels in biofluids, particularly cerebrospinal fluid, are directly linked to the incidence and progression of Alzheimer's. Developing sensitive and reliable methods for screening and evaluating these biomarkers in cerebrospinal fluid can aid in early diagnosis and treatment. This article discusses the impact of Alzheimer's on cerebrospinal fluid and provides an overview of the latest biosensors for detecting amyloid beta and Tau in cerebrospinal fluid samples.
TRAC-TRENDS IN ANALYTICAL CHEMISTRY
(2023)
Article
Clinical Neurology
Yuetiva Deming, Eva Vasiljevic, Autumn Morrow, Jiacheng Miao, Carol Van Hulle, Erin Jonaitis, Yue Ma, Vanessa Whitenack, Gwendlyn Kollmorgen, Norbert Wild, Ivonne Suridjan, Leslie M. Shaw, Sanjay Asthana, Cynthia M. Carlsson, Sterling C. Johnson, Henrik Zetterberg, Kaj Blennow, Barbara B. Bendlin, Qiongshi Lu, Corinne D. Engelman
Summary: APOE epsilon 4-carrier status and epsilon 4 allele count are not sufficient to fully account for the effects of APOE on Alzheimer's disease. A weighted risk score (APOE-npscore) was developed to better explain the genetic effect on neuropathology and provide an improved method for analyzing APOE in relation to AD. This approach outperformed the traditional APOE epsilon 4-carrier status and epsilon 4 allele count in predicting CSF biomarker changes.
ALZHEIMERS & DEMENTIA
(2023)
Article
Medicine, General & Internal
George P. P. Paraskevas, Vasilios C. C. Constantinides, Fotini Boufidou, Ioanna Tsantzali, Efstratios-Stylianos Pyrgelis, Georgios Liakakis, Elisabeth Kapaki
Summary: In addition to typical symptoms, Alzheimer's disease (AD) can also present with atypical clinical manifestations. A study of patients with AD cerebrospinal fluid (CSF) biomarker profile found that 46% had typical symptoms, while 23.5% had mixed presentations and 15.3% had atypical presentations. Some of these atypical presentations may need to be included in diagnostic criteria.
Article
Neurosciences
Christiana Bjorkli, Claire Louet, Trude Helen Flo, Mary Hemler, Axel Sandvig, Ioanna Sandvig
Summary: This study utilized intracerebral microdialysis to analyze CSF biomarkers in an AD mouse model, demonstrating that changes in CSF biomarkers can reflect brain pathology and providing a new approach for better understanding CSF biomarkers.
JOURNAL OF ALZHEIMERS DISEASE
(2021)
Article
Clinical Neurology
Katherine W. Turk, Alexandra Geada, Victor E. Alvarez, Weiming Xia, Jonathan D. Cherry, Raymond Nicks, Gaoyuan Meng, Sarah Daley, Yorghos Tripodis, Bertrand R. Huber, Andrew E. Budson, Brigid Dwyer, Neil W. Kowall, Robert C. Cantu, Lee E. Goldstein, Douglas I. Katz, Robert A. Stern, Michael L. Alosco, Jesse Mez, Ann C. McKee, Thor D. Stein
Summary: CSF levels of p-tau(231) were higher in CTE patients, indicating it may be a potential biomarker for CTE diagnosis. Additionally, A beta(1-42) levels were lower in CTE patients, suggesting further investigation is needed for its role in CTE. The study highlights the differences in CSF analytes between CTE and AD patients.
ALZHEIMERS RESEARCH & THERAPY
(2022)
Article
Medical Laboratory Technology
Kaj Blennow, Erik Stomrud, Henrik Zetterberg, Niels Borlinghaus, Veronika Corradini, Ekaterina Manuilova, Laura Muller-Hubner, Frances-Catherine Quevenco, Sandra Rutz, Oskar Hansson
Summary: This study evaluated the analytical performance of second-generation Elecsys CSF Gen II immunoassays and adjusted existing cut-offs to evaluate their potential utility in clinical routine. The findings suggest that the Gen II immunoassays have potential utility in aiding the diagnosis of Alzheimer's disease.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2023)
Review
Geriatrics & Gerontology
Jiang Chen, Jun-Sheng Chen, Song Li, Fengning Zhang, Jie Deng, Ling-Hui Zeng, Jun Tan
Summary: Decades of research have shown that amyloid-beta (Aβ) plays an undeniable role in the development of Alzheimer's disease (AD). However, the focus on the pathological effects of Aβ may overshadow the significance of its metabolic precursor, amyloid precursor protein (APP), in the occurrence and progression of AD. This review explores the various roles of APP in AD, including its structure, functions, enzymatic processing, and potential therapeutic approaches to targeting APP to ameliorate AD pathologies and halt disease progression.
Article
Biochemistry & Molecular Biology
Rhett J. Britton, James M. Hutchison, Charles R. Sanders
Summary: In Alzheimer's disease (AD) research, the proteins of interest are amyloid precursor protein (APP) and tau, which play crucial roles in the disease mechanism. The relationship between A beta and tau pathologies remains unclear, with studies suggesting that A beta may induce or enhance tau protein formation in neurofibrillary tangles.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2021)
Article
Neurosciences
Yifei Sun, Abhay Moghekar, Anja Soldan, Corinne Pettigrew, Barry Greenberg, Marilyn Albert, Mei-Cheng Wang
Summary: Using a new analytical approach, this study investigated the patterns of biomarker change prior to the onset of mild cognitive impairment (MCI) symptoms in Alzheimer's disease (AD). The findings demonstrated that A beta(42)/A beta(40) decreased, and t-tau and p-tau(181) increased among participants who progressed to MCI, while CSF biomarkers remained relatively stable in participants who did not progress to MCI. Furthermore, APOE4 carriers showed lower A beta(42)/A beta(40) levels at each point of the mean curves, and female sex was associated with higher levels of certain biomarkers among non-progressors.
JOURNAL OF ALZHEIMERS DISEASE
(2023)
Article
Immunology
Anniella Isgren, Joel Jakobsson, Erik Palsson, Carl Johan Ekman, Anette G. M. Johansson, Carl Sellgren, Kaj Blennow, Henrik Zetterberg, Mikael Landen
BRAIN BEHAVIOR AND IMMUNITY
(2015)
Article
Clinical Neurology
Sindre Rolstad, Joel Jakobsson, Carl Sellgren, Anniella Isgren, Carl Johan Ekman, Maria Bjerke, Kaj Blennow, Henrik Zetterberg, Erik Palsson, Mikael Landen
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2015)
Article
Psychiatry
Joel Jakobsson, Erik Palsson, Carl Sellgren, Frida Rydberg, Agneta Ekman, Henrik Zetterberg, Kaj Blennow, Mikael Lander
BRITISH JOURNAL OF PSYCHIATRY
(2016)
Article
Clinical Neurology
Viktoria Johansson, Joel Jakobsson, Rebecca G. Fortgang, Henrik Zetterberg, Kaj Blennow, Tyrone D. Cannon, Christina M. Hultman, Lennart Wetterberg, Mikael Landen
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
(2017)
Article
Biochemistry & Molecular Biology
N. Yoshimi, T. Futamura, S. E. Bergen, Y. Iwayama, T. Ishima, C. Sellgren, C. J. Ekman, J. Jakobsson, E. Palsson, K. Kakumoto, Y. Ohgi, T. Yoshikawa, M. Landen, K. Hashimoto
MOLECULAR PSYCHIATRY
(2016)
Review
Clinical Neurology
Claire Bridel, Wessel N. van Wieringen, Henrik Zetterberg, Betty M. Tijms, Charlotte E. Teunissen, Jose C. Alvarez-Cermeno, Ulf Andreasson, Markus Axelsson, David C. Backstrom, Ales Bartos, Maria Bjerke, Kaj Blennow, Adam Boxer, Lou Brundin, Joachim Burman, Tove Christensen, Lenka Fialova, Lars Forsgren, Jette L. Frederiksen, Magnus Gisslen, Elizabeth Gray, Martin Gunnarsson, Sara Hall, Oskar Hansson, Megan K. Herbert, Joel Jakobsson, Jan Jessen-Krut, Shorena Janelidze, Gudmundur Johannsson, Michael Jonsson, Ludwig Kappos, Mohsen Khademi, Michael Khalil, Jens Kuhle, Mikael Landen, Ville Leinonen, Giancarlo Logroscino, Ching-Hua Lu, Jan Lycke, Nadia K. Magdalinou, Andrea Malaspina, Niklas Mattsson, Lieke H. Meeter, Sanjay R. Mehta, Signe Modvig, Tomas Olsson, Ross W. Paterson, Josue Perez-Santiago, Fredrik Piehl, Yolande A. L. Pijnenburg, Okko T. Pyykko, Oskar Ragnarsson, Julio C. Rojas, Jeppe Romme Christensen, Linda Sandberg, Carole S. Scherling, Jonathan M. Schott, Finn T. Sellebjerg, Isabella L. Simone, Tobias Skillback, Morten Stilund, Peter Sundstrom, Anders Svenningsson, Rosanna Tortelli, Carla Tortorella, Alessandro Trentini, Maria Troiano, Martin R. Turner, John C. van Swieten, Mattias Vagberg, Marcel M. Verbeek, Luisa M. Villar, Pieter Jelle Visser, Anders Wallin, Andreas Weiss, Carsten Wikkelso, Edward J. Wild
Article
Psychiatry
Ruyue Zhang, Jie Song, Anniella Isgren, Joel Jakobsson, Kaj Blennow, Carl M. Sellgren, Henrik Zetterberg, Sarah E. Bergen, Mikael Landen
TRANSLATIONAL PSYCHIATRY
(2020)
Article
Psychiatry
Anette G. M. Johansson, Malin Kallman, Lennart Hogman, Marianne Kristiansson, Hakan Fischer, Sven Bolte
Article
Biochemistry & Molecular Biology
Andreas Goteson, Anniella Isgren, Lina Jonsson, Timea Sparding, Erik Smedler, Aurimantas Pelanis, Henrik Zetterberg, Joel Jakobsson, Erik Palsson, Jessica Holmen-Larsson, Mikael Landen
Summary: The study identified four novel CSF protein associations with bipolar disorder, shedding new light on the central nervous system processes implicated in bipolar disorder.
MOLECULAR PSYCHIATRY
(2021)
Article
Psychiatry
Andreas Goteson, Anniella Isgren, Timea Sparding, Jessica Holmen-Larsson, Joel Jakobsson, Erik Palsson, Mikael Landen
Summary: In this study, novel protein associations with bipolar disorder were identified using proximity extension assay in blood serum samples. The researchers found 32 proteins significantly associated with bipolar disorder, with some associations potentially influenced by psychiatric drugs. The study highlighted MMP-7 as a potential biomarker for lithium-induced nephropathy.
TRANSLATIONAL PSYCHIATRY
(2022)
Article
Biochemistry & Molecular Biology
Johan Sandberg, Caroline Hansson, Andreas Goteson, Erik Joas, Joel Jakobsson, Erik Palsson, Mikael Landen
Summary: This study aimed to identify novel candidate biomarkers for suicidal behavior. Proteins associated with prospective suicide attempts were identified in patients with bipolar disorder, providing potential targets for suicide prevention.
MOLECULAR PSYCHIATRY
(2022)
Article
Biochemistry & Molecular Biology
Anniella Isgren, Andreas Goteson, Jessica Holmen-Larsson, Aurimantas Pelanis, Carl Sellgren, Erik Joas, Timea Sparding, Henrik Zetterberg, Erik Smedler, Joel Jakobsson, Mikael Landen
Summary: The pathophysiology of bipolar disorder is not well understood. This explorative study found that cerebrospinal fluid (CSF) concentrations of growth hormone were lower in bipolar disorder patients, suggesting a potential involvement of growth hormone in the development of bipolar disorder.
MOLECULAR PSYCHIATRY
(2022)
Article
Immunology
Anniella Isgren, Carl Sellgren, Carl-Johan Ekman, Jessica Holmen-Larsson, Kaj Blennow, Henrik Zetterberg, Joel Jakobsson, Mikael Landen
BRAIN BEHAVIOR AND IMMUNITY
(2017)
Article
Medicine, General & Internal
Noriko Yoshimi, Takashi Futamura, Keiji Kakumoto, Alireza M. Salehi, Carl M. Sellgren, Jessica Holmen-Larsson, Joel Jakobssong, Erik Palssong, Mikael Landen, Kenji Hashimoto